Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500?

AbbVie is highlighted as a dividend growth standout, with a forward dividend yield of about 3% and a forward P/E near 16x. The article cites adjusted EPS of roughly $10 in 2025, rising to $14.24 this year and $16.23 in 2027, while the payout ratio remains manageable at 42%. Humira erosion is being offset by Skyrizi and Rinvoq, supporting continued dividend increases of 5% to 6% annually.

Analysis

ABBV looks less like a classic yield trap and more like a de-risked patent-cycle recovery that is still being priced as if durability is uncertain. The key second-order effect is that a visible step-up in earnings power should progressively compress perceived payout risk, which can attract a second wave of buyers from income mandates that previously screened it out on payout-quality concerns. That creates a self-reinforcing setup: better coverage drives multiple stability, which supports buybacks and dividend growth, which further broadens ownership.

Relative valuation versus other large pharma names is the wrong anchor unless you adjust for trajectory, not just static multiple. Names with cheaper near-term multiples but declining earnings tend to become value traps once free cash flow weakens and capital allocation gets defensive; ABBV’s implied advantage is that it can keep returning capital while still funding pipeline/portfolio reinvestment. The market should increasingly treat immunology execution as the core risk factor, not the old patent-cliff narrative.

The main tail risk is that consensus has become too comfortable with a clean earnings glidepath, so any slowdown in the growth vector or pricing pressure in the flagship franchise would hit the stock harder than the headline 3% yield suggests. On a 6-12 month horizon, the more relevant catalyst is whether management can keep guiding to enough earnings acceleration to justify maintaining a premium multiple versus peers; if that confidence slips, ABBV can re-rate down quickly even without a fundamental collapse. Conversely, if earnings revisions keep ticking up, the stock can grind higher with limited volatility because the dividend acts as a floor for long-only demand.

Key Decisions for Investors

• Go long ABBV on pullbacks over the next 1-3 months; target a total-return setup where dividend support reduces downside while earnings revisions can re-rate the stock. Use a tighter stop if forward estimates flatten for two consecutive quarters.
• Pair trade: long ABBV / short PFE for 6-12 months. The thesis is earnings durability versus earnings erosion; this isolates execution quality and lowers sector beta.
• For income portfolios, prefer ABBV over lower-yielding large-cap defensives only if the mandate can tolerate some patent and pipeline risk; the risk/reward is better than many consumer staple dividend proxies that are already fully valued.
• If the stock rerates toward a materially richer multiple without another upward revision to EPS, consider selling covered calls 3-6 months out to monetize the combination of income and mean-reversion risk.